[Donor- derived CD19 chimeric antigen receptor T cells for relapsed B cell malignancies after allogeneic hematopoietic stem cell transplantations].
作者信息
Jin X, Wu R M, Zhao M F
出版信息
Zhonghua Xue Ye Xue Za Zhi. 2016 Aug 14;37(8):725-8. doi: 10.3760/cma.j.issn.0253-2727.2016.08.021.
Abstract
摘要
相似文献
1
[Donor- derived CD19 chimeric antigen receptor T cells for relapsed B cell malignancies after allogeneic hematopoietic stem cell transplantations].异基因造血干细胞移植后复发B细胞恶性肿瘤的供体来源CD19嵌合抗原受体T细胞
Zhonghua Xue Ye Xue Za Zhi. 2016 Aug 14;37(8):725-8. doi: 10.3760/cma.j.issn.0253-2727.2016.08.021.
2
Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia.半相合CD19嵌合抗原受体T细胞与干细胞共同输注在难治性急性淋巴细胞白血病中实现了完全供者植入。
J Hematol Oncol. 2016 Nov 25;9(1):131. doi: 10.1186/s13045-016-0357-z.
3
Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies.异基因造血干细胞移植后在B细胞恶性肿瘤中输注异基因CD19嵌合抗原受体T细胞。
J Hematol Oncol. 2017 Jan 31;10(1):35. doi: 10.1186/s13045-017-0405-3.
4
[Efficacy of CD19 Chimeric Antigen Receptors T Cells in the Treatment of Relapsed Patients with B Cell Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation].CD19嵌合抗原受体T细胞治疗异基因造血干细胞移植后复发的B细胞急性淋巴细胞白血病患者的疗效
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2019 Aug;27(4):1040-1045. doi: 10.19746/j.cnki.issn.1009-2137.2019.04.008.
5
Development and application of CD19-specific T cells for adoptive immunotherapy of B cell malignancies.用于B细胞恶性肿瘤过继性免疫治疗的CD19特异性T细胞的开发与应用
Blood Cells Mol Dis. 2004 Jul-Aug;33(1):83-9. doi: 10.1016/j.bcmd.2004.03.003.
6
Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation.供体来源的靶向CD19的T细胞输注可诱导复发的B细胞急性淋巴细胞白血病患者达到微小残留病阴性缓解，这些患者在单倍体造血干细胞移植后对供体淋巴细胞输注无反应。
Br J Haematol. 2017 Nov;179(4):598-605. doi: 10.1111/bjh.14923. Epub 2017 Oct 26.
7
[Efficacy and safety of CD19 chimeric antigen receptor T cells for the treatment of 22 patients with B-cell lymphoma].CD19嵌合抗原受体T细胞治疗22例B细胞淋巴瘤的疗效与安全性
Zhonghua Xue Ye Xue Za Zhi. 2019 Apr 14;40(4):276-280. doi: 10.3760/cma.j.issn.0253-2727.2019.04.003.
8
Donor-derived CAR-T Cells Serve as a Reduced-intensity Conditioning Regimen for Haploidentical Stem Cell Transplantation in Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: Case Report and Review of the Literature.供体来源的 CAR-T 细胞作为减轻强度预处理方案，用于治疗复发/难治性急性淋巴细胞白血病的单倍体相合干细胞移植：病例报告及文献复习。
J Immunother. 2018 Jul/Aug;41(6):306-311. doi: 10.1097/CJI.0000000000000233.
9
[Chimeric antigen receptors T cells in treatment of a relapsed pediatric acute lymphoblastic leukemia, relapse after allogenetic hematopoietic stem cell transplantation: case report and review of literature review].[嵌合抗原受体T细胞治疗复发性儿童急性淋巴细胞白血病，异基因造血干细胞移植后复发：病例报告及文献复习]
Zhonghua Xue Ye Xue Za Zhi. 2016 Feb;37(2):115-8. doi: 10.3760/cma.j.issn.0253-2727.2016.02.006.
10
Donor-derived CD19-targeted T cells in allogeneic transplants.同种异体移植中供体来源的靶向CD19的T细胞。
Curr Opin Hematol. 2015 Nov;22(6):497-502. doi: 10.1097/MOH.0000000000000178.
本文引用的文献
1
Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia.表达CD19嵌合抗原受体的自体或供体来源T细胞在伴有髓外白血病的成人B淋巴细胞白血病中的耐受性和疗效
Oncoimmunology. 2015 May 26;4(11):e1027469. doi: 10.1080/2162402X.2015.1027469. eCollection 2015 Nov.
2
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma.用于治疗多发性骨髓瘤的靶向CD19的嵌合抗原受体T细胞
N Engl J Med. 2015 Sep 10;373(11):1040-7. doi: 10.1056/NEJMoa1504542.
3
Multiplex Genome-Edited T-cell Manufacturing Platform for "Off-the-Shelf" Adoptive T-cell Immunotherapies.用于“现货”过继性 T 细胞免疫疗法的多重基因组编辑 T 细胞制造平台。
Cancer Res. 2015 Sep 15;75(18):3853-64. doi: 10.1158/0008-5472.CAN-14-3321. Epub 2015 Jul 16.
4
T-cell and natural killer cell therapies for hematologic malignancies after hematopoietic stem cell transplantation: enhancing the graft-versus-leukemia effect.造血干细胞移植后血液系统恶性肿瘤的T细胞和自然杀伤细胞疗法：增强移植物抗白血病效应
Haematologica. 2015 Jun;100(6):709-19. doi: 10.3324/haematol.2014.113860.
5
Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation.可诱导的半胱天冬酶-9自杀基因可控制单倍体干细胞移植后完全异体T细胞产生的不良反应。
Blood. 2015 Jun 25;125(26):4103-13. doi: 10.1182/blood-2015-02-628354. Epub 2015 May 14.
6
Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs.肿瘤吲哚胺2,3-双加氧酶（IDO）抑制CD19嵌合抗原受体T细胞，并被淋巴细胞清除药物下调。
Blood. 2015 Jun 18;125(25):3905-16. doi: 10.1182/blood-2015-01-621474. Epub 2015 May 4.
7
Natural killer cell therapy in children with relapsed leukemia.复发白血病患儿的自然杀伤细胞疗法
Pediatr Blood Cancer. 2015 Aug;62(8):1468-72. doi: 10.1002/pbc.25555. Epub 2015 Apr 30.
8
Early transduction produces highly functional chimeric antigen receptor-modified virus-specific T-cells with central memory markers: a Production Assistant for Cell Therapy (PACT) translational application.早期转导产生具有中央记忆标志物的高功能嵌合抗原受体修饰的病毒特异性 T 细胞：细胞治疗的生产助理（PACT）的转化应用。
J Immunother Cancer. 2015 Feb 18;3:5. doi: 10.1186/s40425-015-0049-1. eCollection 2015.
9
Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9.利用CRISPR/Cas9对人类造血干细胞和效应细胞中的基因进行高效敲除。
Cell Stem Cell. 2014 Nov 6;15(5):643-52. doi: 10.1016/j.stem.2014.10.004.
10
Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies.迅速传播：嵌合抗原受体T细胞疗法治疗血液系统恶性肿瘤
Immunol Rev. 2015 Jan;263(1):68-89. doi: 10.1111/imr.12243.
Zotero 插件